Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Lyell Immunopharma, Inc. LYEL

Healthcare  —  Biotechnology
9.85 (0.27) (2.67%) as of 25 Sep
Market cap
$248.0M
P/E
0.0×
Cash Flow Champion (3y) Insider Buys (last 12m)
Growth Flags show if company had growth for consecutive years,
Insider Buys alert about insiders buying in the last 12 month
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Lyell Immunopharma, Inc. (LYEL) Business Profile

Updated before January 2025

Company Overview

Lyell Immunopharma, Inc. (LYEL) is a biotechnology company dedicated to advancing the field of cell therapy to treat cancer. Founded in 2018, Lyell is headquartered in South San Francisco, California. The company was established by a team of leading scientists and entrepreneurs, including Dr. Rick Klausner, a former director of the National Cancer Institute, and Dr. Maria Fardis, a seasoned biotech executive. Lyell’s mission is to develop innovative therapies that enhance the functionality and durability of T cells, which are critical components of the immune system, to improve outcomes for cancer patients.

The company is led by a strong leadership team with deep expertise in immunology, oncology, and cell therapy. Dr. Rick Klausner serves as the Executive Chairman, while Dr. Liz Homans, a seasoned executive with extensive experience in the biotech industry, serves as the Chief Executive Officer. Lyell’s leadership team also includes Dr. Nick Restifo, a pioneer in T cell therapy, and other prominent figures in the field of biotechnology.

Core Business Segments

Lyell Immunopharma focuses on developing cell-based immunotherapies for cancer treatment. The company’s core business segments include:

1. T Cell Reprogramming Technologies

Lyell has developed proprietary technologies aimed at reprogramming T cells to enhance their functionality and durability. These technologies include:

  • Exhaustion Resistance (ER): A platform designed to prevent T cell exhaustion, a common challenge in cell therapy where T cells lose their ability to fight cancer over time.
  • Stemness: A technology that maintains T cells in a less differentiated state, enabling them to proliferate and persist longer in the body.

2. Pipeline of Cell Therapy Products

Lyell is advancing a robust pipeline of cell therapy candidates targeting various types of cancer. Key products in development include:

  • LYL797: A CAR-T cell therapy targeting ROR1, a protein expressed in multiple solid tumors.
  • LYL845: A TIL (tumor-infiltrating lymphocyte) therapy designed to enhance the functionality of T cells extracted from tumors.

3. Research and Development Services

Lyell collaborates with academic institutions and industry partners to advance the science of cell therapy. The company invests heavily in R&D to discover and develop next-generation immunotherapies.

Business Model

Lyell Immunopharma operates on a business model centered around innovation, collaboration, and commercialization. The company generates revenue through:

  • Partnerships and Collaborations: Lyell collaborates with leading academic institutions and pharmaceutical companies to co-develop therapies and share intellectual property.
  • Licensing Agreements: The company licenses its proprietary technologies to other biotech firms, generating revenue through upfront payments, milestones, and royalties.
  • Product Commercialization: Once its therapies receive regulatory approval, Lyell plans to commercialize them directly or through partnerships.

Lyell’s approach integrates cutting-edge science with a focus on addressing unmet medical needs in oncology. The company invests significantly in R&D to maintain its competitive edge and drive innovation.

Strategic Direction

Lyell Immunopharma is committed to advancing the field of cell therapy and achieving long-term growth. Key strategic priorities include:

  • Expanding the Pipeline: Lyell aims to broaden its portfolio of cell therapy candidates by targeting additional cancer types and exploring new therapeutic modalities.
  • Global Expansion: The company plans to establish a global presence by entering new markets and forming strategic partnerships with international organizations.
  • Sustainability Goals: Lyell is dedicated to sustainable practices in its operations, including reducing its environmental footprint and promoting ethical research practices.
  • Technological Innovation: The company continues to invest in cutting-edge technologies to enhance the efficacy and safety of its therapies.

Competitive Landscape

Lyell operates in a highly competitive biotechnology sector, facing competition from both established companies and emerging startups. Key competitors include:

  • Kite Pharma (a Gilead company): A leader in CAR-T cell therapy with approved products like Yescarta.
  • Novartis: A major player in cell therapy with its CAR-T product, Kymriah.
  • Adaptimmune: Focused on TCR (T cell receptor) therapies for cancer.
  • Bluebird Bio: Known for its work in gene and cell therapies.

Lyell differentiates itself through its proprietary technologies and focus on addressing the limitations of existing cell therapies, such as T cell exhaustion and durability.

Risk Factors

Like any biotechnology company, Lyell faces several risks, including:

  • Regulatory Challenges: The development and approval of cell therapies are subject to stringent regulatory requirements, which can delay commercialization.
  • Market Dependence: Lyell’s success depends on the commercial viability of its therapies, which are still in the development stage.
  • Supply Chain Disruptions: The company relies on a complex supply chain for the production of its therapies, making it vulnerable to disruptions.
  • Competition: Intense competition in the biotech sector could impact Lyell’s market share and profitability.
  • Financial Risks: As a pre-revenue company, Lyell depends on external funding to finance its operations, which could be affected by market conditions.

Recent Developments

Lyell has made significant progress in advancing its pipeline and corporate strategy. Recent developments include:

  • Clinical Trials: The company initiated clinical trials for LYL797 and LYL845, marking a major milestone in its journey toward commercialization.
  • Partnerships: Lyell entered into a collaboration with a leading pharmaceutical company to co-develop cell therapies.
  • Technological Advancements: The company unveiled new data demonstrating the efficacy of its exhaustion resistance and stemness technologies.
  • Corporate Initiatives: Lyell expanded its leadership team and board of directors, bringing in experts with extensive experience in oncology and cell therapy.

Investment Considerations

Investors considering Lyell Immunopharma should weigh the following factors:

Strengths

  • Innovative Technology: Lyell’s proprietary platforms address critical challenges in cell therapy, giving it a competitive edge.
  • Strong Leadership: The company is led by a team of experts with a proven track record in biotechnology.
  • Robust Pipeline: Lyell’s diverse pipeline targets multiple cancer types, increasing its market potential.

Risks

  • Early-Stage Company: As a pre-revenue company, Lyell faces significant financial and operational risks.
  • Regulatory Uncertainty: The approval process for cell therapies is complex and time-consuming.
  • Market Competition: Intense competition from established players could impact Lyell’s growth prospects.

Conclusion

Lyell Immunopharma is at the forefront of innovation in cell therapy, leveraging its proprietary technologies to address unmet medical needs in oncology. While the company faces significant risks as an early-stage biotech firm, its strong leadership, robust pipeline, and focus on innovation position it for long-term success. As Lyell continues to advance its therapies and expand its global presence, it has the potential to become a leader in the field of cell-based immunotherapy.